Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/112712
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Thakkar, V. | - |
dc.contributor.author | Patterson, K. | - |
dc.contributor.author | Stevens, W. | - |
dc.contributor.author | Wilson, M. | - |
dc.contributor.author | Roddy, J. | - |
dc.contributor.author | Sahhar, J. | - |
dc.contributor.author | Proudman, S. | - |
dc.contributor.author | Hissaria, P. | - |
dc.contributor.author | Nikpour, M. | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Clinical Rheumatology, 2018; 37(6):1563-1571 | - |
dc.identifier.issn | 0770-3198 | - |
dc.identifier.issn | 1434-9949 | - |
dc.identifier.uri | http://hdl.handle.net/2440/112712 | - |
dc.description | Published online: 23 April 2018 | - |
dc.description.abstract | Studies suggest elevated serum intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) levels may be markers of pulmonary arterial hypertension in systemic sclerosis (SSc-PAH). We sought to evaluate whether ICAM-1 and VCAM-1 levels are useful screening biomarkers for incident SSc-PAH. In this cross-sectional study, four groups were selected from the Australian Scleroderma Cohort Study: group 1 (n = 15) had definite PAH; group 2 (n = 19) had interstitial lung disease (ILD); group 3 (n = 30) were SSc-controls; and group 4 (n = 34) were healthy controls. Serum ICAM-1 and VCAM-1 levels were measured using the Millipore Milliplex MAP Human 2-Plex Panel. There were no differences in ICAM-1 levels in the PAH versus ILD group (263.0 ± 85.4 vs 380.4 ± 168.3 ng/mL, p = 0.136), SSc-controls (263.0 ± 85.4 vs 253.1 ± 98.0 ng/mL, p = 1.00), or healthy controls (263.0 ± 85.4 vs 201.8 ± 57.2 ng/mL, p = 0.093). Similarly, there were no differences in VCAM-1 level in PAH versus ILD groups (1476.2 ± 434.9 vs 1424.8 ± 527.6 ng/mL, p = 1.00) and SSc-controls (1476.2 ± 434.9 vs 1409.5 ± 341.1 ng/mL, p = 1.00). SSc subjects had significantly higher levels of ICAM-1 (297.4 ± 134.0 vs 201.8 ± 57.2 ng/mL, p < 0.0001) and VCAM-1 compared to healthy controls (1432.7 ± 427.4 vs 1125.6 ± 273.4 ng/mL, p < 0.0001). Neither ICAM-1 nor VCAM-1 is a specific screening biomarker of SSc-PAH. Instead, increased levels of these adhesion molecules in SSc, irrespective of pulmonary complications, suggest that they may play a role in SSc pathogenesis. | - |
dc.description.statementofresponsibility | Vivek Thakkar, Karen A. Patterson, Wendy Stevens, Michelle Wilson, Janet Roddy, Joanne Sahhar, Susanna Proudman, Pravin Hissaria, Mandana Nikpour | - |
dc.language.iso | en | - |
dc.publisher | Springer London | - |
dc.rights | © International League of Associations for Rheumatology (ILAR) 2018 | - |
dc.source.uri | http://dx.doi.org/10.1007/s10067-018-4081-7 | - |
dc.subject | Biomarker | - |
dc.subject | Intercellular adhesion molecule-1 (ICAM-1) | - |
dc.subject | Pulmonary arterial hypertension | - |
dc.subject | Screening | - |
dc.subject | Systemic sclerosis | - |
dc.subject | Vascular cell adhesion molecule-1 (VCAM-1) | - |
dc.title | Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1007/s10067-018-4081-7 | - |
dc.relation.grant | http://purl.org/au-research/grants/nhmrc/1126370 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Proudman, S. [0000-0002-3046-9884] | - |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.